We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
76
CALL
DELISTED
Adverum Biotechnologies
ADVM
$4.16M 0.3%
40,340
+4,470
+12% +$669K
ACAD icon
77
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$4.13M 0.3%
100,000
-100,000
-50% -$4.32M
BMY.RT
78
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$4.05M 0.29%
1,800,000
+700,000
+64% +$2M
AGEN
79
Agenus
AGEN
$312M
$3.8M 0.28%
+48,402
New +$3.77M
ARVN icon
80
CALL
Arvinas
ARVN
$518M
$3.77M 0.27%
159,700
+53,600
+51% +$1.55M
KDMN
81
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.67M 0.27%
936,615
-44,455
-5% -$187K
ARYBU
82
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$3.5M 0.25%
+318,206
New +$3.61M
TVRD
83
Tvardi Therapeutics
TVRD
$19.7M
$3.48M 0.25%
7,598
– –
CMRX
84
DELISTED
Chimerix, Inc.
CMRX
$3.4M 0.25%
+1,364,044
New +$4.03M
KALA icon
85
KALA BIO
KALA
$14.1M
$3.39M 0.25%
+181
New +$4.16M
SRRA
86
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.35M 0.24%
313,890
+304,232
+3,150% +$3.62M
ZGNX
87
DELISTED
Zogenix, Inc.
ZGNX
$3.27M 0.24%
182,591
-324,968
-64% -$7.96M
ACET icon
88
Adicet Bio
ACET
$85.2M
$3.26M 0.24%
17,142
+4,173
+32% +$1.06M
EIDX
89
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$3.18M 0.23%
63,011
-36,989
-37% -$1.66M
ADVM
90
PUT
DELISTED
Adverum Biotechnologies
ADVM
$3.04M 0.22%
29,480
+20,000
+211% +$3M
VINC
91
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3M 0.22%
+12,088
New +$2.46M
PAND
92
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$2.98M 0.22%
+260,000
New +$4.44M
MYOV
93
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
$2.81M 0.2%
+200,000
New +$3.72M
MDGL icon
94
Madrigal Pharmaceuticals
MDGL
$10.8B
$2.81M 0.2%
23,654
-18,900
-44% -$2.05M
EIGR
95
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.77M 0.2%
+11,344
New +$3.53M
MCRB icon
96
Seres Therapeutics
MCRB
$46.8M
$2.7M 0.2%
+4,772
New +$1.59M
AGTC
97
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.65M 0.19%
545,884
– –
KA
98
DELISTED
Kineta, Inc. Common Stock
KA
$2.63M 0.19%
+17,071
New +$3.21M
ASMB icon
99
Assembly Biosciences
ASMB
$498M
$2.59M 0.19%
13,122
– –
ITCI
100
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.57M 0.19%
+100,000
New +$2.28M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.